Kant Drugs Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 17-06-2024
- Paid Up Capital ₹ 3.15 Cr
as on 17-06-2024
- Company Age 23 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.24 Cr
as on 17-06-2024
- Revenue 12.11%
(FY 2022)
- Profit 198.19%
(FY 2022)
- Ebitda 28.00%
(FY 2022)
- Net Worth 14.51%
(FY 2022)
- Total Assets 18.06%
(FY 2022)
About Kant Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 3.15 Cr.
The company currently has active open charges totaling ₹4.24 Cr.
Kusha, Sandeep Rastogi, Anurag Das, and Seven other members serve as directors at the Company.
- CIN/LLPIN
U24232UP2001PTC025855
- Company No.
025855
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Feb 2001
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Uttar Pradesh, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Kant Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vaibhav Rastogi  | Managing Director | 18-Jun-2009 | Current |
Board Members(9)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Manoj Rastogi | Director | 05-Feb-2001 | Current |
| Kusha | Director | 05-Feb-2001 | Current |
| Anurag Das | Director | 01-Mar-2010 | Current |
| Sandeep Rastogi | Director | 18-Jun-2009 | Current |
| Aruna Das | Director | 05-Feb-2001 | Current |
| Tribhuwan Das | Director | 05-Feb-2001 | Current |
Financial Performance of Kant Drugs.
Kant Drugs Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 12.11% increase. The company also saw a substantial improvement in profitability, with a 198.19% increase in profit. The company's net worth Soared by an impressive increase of 14.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kant Drugs?
In 2021, Kant Drugs had a promoter holding of 29.00% and a public holding of 71.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
M.M. Remedies Private LimitedActive 26 years 7 monthsSandeep Rastogi, Anurag Das and 5 more are mutual person
- Das Drugs Private LimitedActive 27 years 6 months
Anurag Das, Aruna Das and 5 more are mutual person
- Four Seasons Pharmaceuticals Private LimitedActive 12 years 8 months
Tribhuwan Das and Vaibhav Rastogi are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 27 Aug 2021 | ₹9.90 M | Open |
Hdfc Bank Limited Creation Date: 04 Jun 2016 | ₹3.25 Cr | Open |
How Many Employees Work at Kant Drugs?
Kant Drugs has a workforce of 57 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kant Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kant Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
